CL
NVO

CIM LLC’s Novo Nordisk NVO Stock Holding History

CIM LLC’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.79K Hold
100
– – ﹤0.01% 171
2026
Q1 		$3.67K Buy
+100
New +$4.74K ﹤0.01% 168

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

CIM LLC's NVO Position: Q2 2026 in Review

CIM LLC reduced its Novo Nordisk (NVO) stake by 27% in Q2 2026, selling an estimated $4.36M and leaving 273,341 shares worth $13.1M. The position accounts for 1.69% of the portfolio, ranked #21.

CIM LLC first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $28.8M in Q2 2024. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • CIM LLC held 273,341 shares of Novo Nordisk worth $13.1M as of Q2 2026.
  • CIM LLC sold 101,476 Novo Nordisk shares in Q2 2026, an estimated $4.36M.
  • Novo Nordisk made up 1.69% of CIM LLC's portfolio in Q2 2026, its #21 holding.
  • CIM LLC first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
  • CIM LLC's Novo Nordisk position peaked at $28.8M in Q2 2024.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on CIM LLC's 13F filing for Q2 2026, filed 13 Aug 2026.